Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on organ fibrosis and inflammatory disease. In China, through its controlling interest in Gyre Pharmaceuticals, it markets ETUARY (pirfenidone), an established treatment for idiopathic pulmonary fibrosis, and is advancing other fibrosis-related products. Lead pipeline candidate F351 (hydronidone) targets liver fibrosis, including chronic hepatitis B–associated disease in China and MASH-related fibrosis in the U.S. The company combines China commercialization with U.S. development programs and a broader small-molecule pipeline.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 29.7 | — | -2 | — |
| Q3 2025 | 30.6 | — | 3.6 | — |
| Q4 2025 | 37.2 | — | -1.7 | — |
| Q1 2026 | 22.5 | — | -8.7 | — |
| Q2 2026 | 29.1 | -2.1% | -11.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Ballard Power Systems Inc. (BLDP), SLR Investment Corp. (SLRC), Allogene Therapeutics, Inc. (ALLO), Tiptree Inc. (TIPT), Sprout Social, Inc. (SPT), AGNT, Inc (AGNT)